April 19, 2018 / 12:08 PM / 3 months ago

BRIEF-Krystal Biotech’S Kb103 Receives Orphan Medicinal Product Designation In Europe For Dystrophic Epidermolysis Bullosa

April 19 (Reuters) - Krystal Biotech Inc:

* KRYSTAL BIOTECH’S KB103 RECEIVES ORPHAN MEDICINAL PRODUCT DESIGNATION IN EUROPE FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below